Neuroprotective efficacy of EDTA against manganese neurotoxicity: Implications for modulating Parkinsonian syndromes
Objective: This study investigates the neuroprotective potential of ethylenediaminetetraacetic acid (EDTA) in reducing the neurotoxic effects of manganese (Mn), focusing on both motor and non-motor…Targeted Brain Delivery of Rifampicin via PEG-PLA Nanoparticles: A Promising Therapeutic Strategy for Neuroprotection and Disease Modification in Parkinsonian Mouse Models
Objective: This study aimed to design and validate a nanoparticle-based delivery system for rifampicin, with the objective of enhancing its therapeutic efficacy, improving brain targeting,…Targeting IGF2 Signaling for Immune Modulation of Microglia in Parkinson’s Disease
Objective: We propose that IGF2 induces a distinct inflammatory phenotype in macrophages or microglia derived from Parkinson’s disease (PD) patients. Background: Microglia are the resident…Evaluation of Neuroprotective Effect of Terminalia macroptera on Rotenone Induced Parkinson’s Disease in Mice
Objective: This study investigates the neuroprotective effects of an aqueous extract of Terminalia macroptera (AETM) in a rotenone-induced Parkinsonism mouse model. Background: Parkinson’s disease (PD)…Therapeutic restoration of Faecalibacterium prausnitzii in Parkinson’s disease using targeted fructoligosaccharides: a double-blind, placebo-controlled, cross-over trial
Objective: In this study, we evaluated the effect of targeted fructoligosaccharide (FOS) therapy to restore the beneficial butyrate producer Faecalibacterium prausnitzii, one the most highly reduced…Design, synthesis and pharmacological evaluation of 16-pyridylmethylene derivatives of steroidal oximes as antiparkinsonian agents in MPTP-injected mice.
Objective: The objective of the present study is focused on the design and synthesis of 16-pyridyl methylene derivatives of steroidal oximes and further their pharmacological…Exploring the Neuroprotective Potential of Mushroom Extracts in Parkinson’s Disease In-Vitro Models
Objective: This study investigates the potential neuroprotective effects of several mushroom extracts in PD in-vitro models. Background: Parkinson's disease, a progressive condition, involves dysfunction or…TrkB modulator OT-003 reduces dopaminergic cell loss, mitochondrial stress, alpha-synuclein aggregation and motor dysfunction in Parkinson’s disease models.
Objective: To assess efficacy and potency of our proprietary lead compound OT-003, an orally bioavailable small molecule Tropomyosin receptor kinase B (TrkB) modulator, in preclinical…Neurotinib, a Brain Penetrant c-Abl Inhibitor, Prevents Activation and Phosphorylation of c-Abl Kinase and Alpha-Synuclein
Objective: Objective: To investigate Neurotinib, a newly developed allosteric c-Abl inhibitor, as a neuroprotective agent in a murine GBA1-associated Parkinson's disease (PD) model. Background: The…Validating the clinical stage NLRP3 inflammasome inhibitor nibrozetone as a disease-modifying therapeutic for Parkinson’s disease
Objective: We recently confirmed that nibrozetone (RRx-001), a Phase 3 small molecule chemoprotective agent, is a direct NLRP3 inhibitor that is CNS permeable. Nibrozetone displays…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 15
- Next Page »